Customize your search results with filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated : 06/20/2022

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Wilms' tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory acute leukemia.

Condition: Acute Leukemia
Journal: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
Treatment Used: Dendritic Cells Based Immunotherapy
Number of Patients: 11
Published: March 06, 2022
View publication
Summary: Wilms' tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory acute leukemia.

A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies.

Condition: WT1-Positive Tumors
Journal: Scientific reports
Treatment Used: WT2725 WT1-Derived Oligopeptide Vaccine
Number of Patients: 44
Published: November 17, 2021
View publication
Summary: A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies.

Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer.

Condition: Recurrent Ovarian Cancer
Journal: Journal for immunotherapy of cancer
Treatment Used: Autologous WT1-Sensitized T Cells
Number of Patients: 12
Published: August 26, 2021
View publication
Summary: Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer.

Every Beat You Take-The Wilms' Tumor Suppressor WT1 and the Heart.

Journal: International journal of molecular sciences
Published: July 24, 2021
View publication
Summary: Every Beat You Take-The Wilms' Tumor Suppressor WT1 and the Heart.

Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD.

Condition: Acute Myeloid Leukemia (AML)
Journal: Frontiers in immunology
Treatment Used: Combination Therapy with PD-1 Blockade after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
Number of Patients: 1
Published: April 19, 2021
View publication
Summary: Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD.

Friend or foe? The case of Wilms' Tumor 1 (WT1) mutations in acute myeloid leukemia.

Journal: Blood cells, molecules & diseases
Published: February 26, 2021
View publication
Summary: Friend or foe? The case of Wilms' Tumor 1 (WT1) mutations in acute myeloid leukemia.

T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.

Condition: Acute Myeloid Leukemia
Journal: Nature medicine
Treatment Used: T-Cell Receptor Gene Therapy after Hematopoietic Stem Cell Transplantation
Number of Patients: 12
Published: June 26, 2019
View publication
Summary: T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.

Phase I/II Pilot Study of Wilms' Tumor 1 Peptide-Pulsed Dendritic Cell Vaccination Combined With Conventional Chemotherapy in Patients With Head and Neck Cancer.

Condition: Head and Neck Cancer
Journal: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
Treatment Used: Willms' Tumor 1 Peptide-Pulsed Dendritic Cell Vaccination combined with Conventional Chemotherapy
Number of Patients: 11
Published: April 30, 2019
View publication
Summary: Phase I/II Pilot Study of Wilms' Tumor 1 Peptide-Pulsed Dendritic Cell Vaccination Combined With Conventional Chemotherapy in Patients With Head and Neck Cancer.

A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.

Condition: Recurrent malignant glioma
Journal: Cancer immunology, immunotherapy : CII
Treatment Used: Cocktail vaccine of WT1 human leukocyte antigen class I and II peptides
Number of Patients: 14
Published: November 16, 2018
View publication
Summary: A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.

Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer.

Condition: Breast, ovarian, gastric cancer
Journal: Cancer immunology, immunotherapy : CII
Treatment Used: Dendritic cells vaccination with Wilms' tumor protein 1 (WT1)
Number of Patients: 10
Published: October 12, 2018
View publication
Summary: Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer.

Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial.

Condition: Lower-risk Myelodysplastic Syndromes
Journal: Cancer science
Treatment Used: five-day regimen of azacitidine
Number of Patients: 51
Published: July 15, 2018
View publication
Summary: Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial.

Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.

Condition: Acute Myeloid Leukemia (AML)
Journal: Blood advances
Treatment Used: Multivalent WT1 Peptide Vaccine (Galinpepimut-S)
Number of Patients: 22
Published: February 02, 2018
View publication
Summary: Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.
Showing 1-12 of 12

Last Updated : 06/20/2022